Depression and Anxiety Disorder Screening

Depression and anxiety disorder screening is the use of brief validated questionnaires to identify people who probably have a depressive or anxiety disorder among those not already diagnosed, so they can be evaluated further. The best-known instruments are the Patient Health Questionnaire (PHQ-9 and its two-item PHQ-2) for depression and the GAD-7 for generalized anxiety, all designed to be short enough for routine primary care while remaining sensitive to probable cases.

Definition

The administration of brief, validated self-report instruments (such as the PHQ-9, PHQ-2, and GAD-7) to detect probable depressive or anxiety disorders in undiagnosed individuals, with positive screens prompting fuller clinical evaluation rather than constituting a diagnosis.

Scope

The topic covers the rationale, instruments, and measurement logic of depression and anxiety case-finding in general settings, and the way a positive screen leads to confirmatory assessment. It treats screening as a preventive-services and measurement topic; it is not a diagnostic protocol and does not direct care for any individual.

Core questions

• What measurement properties make an instrument suitable for first-stage screening versus severity monitoring?
• How do cut-points trade sensitivity for specificity, and how does that affect false positives in low-prevalence settings?
• Why is a positive PHQ-2 or PHQ-9 a prompt for assessment rather than a diagnosis?
• Where does evidence support screening, and where do guidelines note gaps?

Key concepts

• PHQ-9 and PHQ-2 depression measures
• GAD-7 generalized anxiety measure
• Cut-point and threshold selection
• Sensitivity, specificity, and positive predictive value
• Two-stage screening then confirmatory assessment
• Severity monitoring versus case detection

Mechanisms

These instruments map self-reported symptom frequency over a recent window onto numeric scores; a score at or above a chosen cut-point classifies the respondent as screen-positive. The PHQ-9 operationalizes the nine criterion symptoms of major depression and doubles as a severity and monitoring measure, while the ultra-brief PHQ-2 is used as a first-stage filter whose positives are followed by the full PHQ-9. The GAD-7 performs the analogous role for generalized anxiety and also detects other anxiety disorders with reasonable sensitivity. Because all are calibrated to favor sensitivity, positive results overestimate true cases and require confirmatory clinical assessment.

Clinical relevance

Brief depression and anxiety screens are among the most widely used measurement tools in primary care and are referenced in preventive-services recommendations. This entry explains how the instruments are constructed and interpreted at the program level; it is educational and does not prescribe screening intervals, cut-points, or clinical responses for any individual, which are governed by current guidelines and clinical judgement.

Epidemiology

Depressive and anxiety disorders are highly prevalent in primary-care populations and frequently co-occur, yet a large fraction go undetected without active case-finding. The US Preventive Services Task Force recommends screening adults, including pregnant and postpartum persons, for depression where systems for diagnosis and treatment exist; anxiety screening recommendations have evolved separately and are addressed in their own statements.

Evidence & guidelines

The PHQ-9 (Kroenke 2001) and PHQ-2 (Kroenke 2003) are the validated depression measures behind most screening programs, and the GAD-7 (Spitzer 2006) is the corresponding anxiety measure. The USPSTF (2023) recommends depression screening in adults when accurate diagnosis, effective treatment, and follow-up can be offered, framing the instruments as case-finding rather than diagnostic tools.

History

The Patient Health Questionnaire emerged in the 1990s as a self-administered version of the PRIME-MD diagnostic interview, with the PHQ-9 validated as a brief depression measure in 2001 and the two-item PHQ-2 following in 2003. The GAD-7 was introduced in 2006 to provide a comparably brief anxiety screen. These instruments became the de facto standards as primary care adopted routine behavioral-health measurement.

Debates

Do brief screens over-identify mild or transient distress?

Because cut-points are set to favor sensitivity, screening in low-prevalence settings yields many false positives, raising concern about overdiagnosis and the burden of follow-up unless confirmatory assessment is reliably applied.

Key figures

• Kurt Kroenke
• Robert L. Spitzer
• Janet B. W. Williams
• Bernd Lowe

Seminal works

• kroenke-2001
• kroenke-2003-phq2
• spitzer-2006-gad7

Frequently asked questions

What is the difference between the PHQ-2 and the PHQ-9?

The PHQ-2 is a two-item first-stage screen asking about depressed mood and loss of interest; a positive PHQ-2 is typically followed by the full nine-item PHQ-9, which covers all major-depression criterion symptoms and can also track severity over time.

Can a screening questionnaire diagnose depression or anxiety?

No. Instruments like the PHQ-9 and GAD-7 estimate the probability of a disorder and flag people for further evaluation; a clinical assessment is needed to confirm a diagnosis.